Literature DB >> 19269012

Caspases and inhibitor of apoptosis proteins in cutaneous and mucosal melanoma: expression profile and clinicopathologic significance.

Ni Chen1, Jing Gong, Xueqin Chen, Wentong Meng, Ying Huang, Fang Zhao, Lin Wang, Qiao Zhou.   

Abstract

Malignant melanoma is characterized by apoptotic dysfunction, presumably due to abnormal expression of caspases and inhibitor of apoptosis proteins. However, the expression status and clinicopathologic significance of caspases and inhibitor of apoptosis proteins in cutaneous and particularly in mucosal melanomas have not been established. We investigated the expression of the major caspases (CASP3, 6, 7, 8, 9, and 10) and inhibitor of apoptosis proteins (survivin, CIAP1, CIAP2, XIAP, and Livin) by immunohistochemistry in 52 primary cutaneous and 25 mucosal melanomas, and 24 common nevi. Clinicopathologic and prognostic significance was investigated by statistical analysis. Our data showed that the significantly up-regulated inhibitor of apoptosis proteins in primary cutaneous and mucosal melanomas as compared with nevus (P < .01) were survivin, CIAP1, CIAP2, and Livin. Percentage of cases with positive caspase or IAP immunostaining was not significantly different between primary cutaneous and mucosal melanomas or between lower- and higher-stage melanomas (P > .05). Tumor location (cutaneous versus mucosal), stage, and positive cytoplasmic and nuclear survivin staining correlated significantly with prognosis by univariate analysis (P < .01). Multivariate analysis by Cox regression model showed that the most useful prognostic indicators were tumor location (cutaneous versus mucosal, relative risk = 6.021, 95% confidence interval = 2.623 approximately 13.821, P = .000), stage (relative risk = 4.129, 95% confidence interval = 1.817 approximately 9.383, P = .001), and nuclear survivin staining (relative risk = 3.383, 95% confidence interval = 1.137 approximately 10.008, P = .028).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269012     DOI: 10.1016/j.humpath.2008.12.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  16 in total

1.  Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells.

Authors:  Guorong Li; Coralia Luna; Jianming Qiu; David L Epstein; Pedro Gonzalez
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-06       Impact factor: 4.799

2.  Livin, Survivin and Caspase 3 as early recurrence markers in non-muscle-invasive bladder cancer.

Authors:  Jianwen Wang; Xiaodong Zhang; Ping Wei; Junhui Zhang; Yinong Niu; Ning Kang; Yuxiang Zhang; Weili Zhang; Nianzeng Xing
Journal:  World J Urol       Date:  2014-03-05       Impact factor: 4.226

3.  Removal of Metabolic Liabilities Enables Development of Derivatives of Procaspase-Activating Compound 1 (PAC-1) with Improved Pharmacokinetics.

Authors:  Howard S Roth; Rachel C Botham; Steven C Schmid; Timothy M Fan; Levent Dirikolu; Paul J Hergenrother
Journal:  J Med Chem       Date:  2015-04-20       Impact factor: 7.446

4.  siRNA directed against Livin inhibits tumor growth and induces apoptosis in human glioma cells.

Authors:  Bangqing Yuan; Boli Ran; Shousen Wang; Zheng Liu; Zhaocong Zheng; Hongjie Chen
Journal:  J Neurooncol       Date:  2011-11-16       Impact factor: 4.130

5.  Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Authors:  Scott C Bresler; Le Min; Scott J Rodig; Andrew C Walls; Shuyun Xu; Songmei Geng; F Stephen Hodi; George F Murphy; Christine G Lian
Journal:  Lab Invest       Date:  2016-12-05       Impact factor: 5.662

6.  Procaspase-3 Overexpression in Cancer: A Paradoxical Observation with Therapeutic Potential.

Authors:  Matthew W Boudreau; Jessie Peh; Paul J Hergenrother
Journal:  ACS Chem Biol       Date:  2019-07-16       Impact factor: 5.100

7.  The Combination of Vemurafenib and Procaspase-3 Activation Is Synergistic in Mutant BRAF Melanomas.

Authors:  Jessie Peh; Timothy M Fan; Kathryn L Wycislo; Howard S Roth; Paul J Hergenrother
Journal:  Mol Cancer Ther       Date:  2016-06-13       Impact factor: 6.261

8.  Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities.

Authors:  Howard S Roth; Paul J Hergenrother
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 9.  Update on primary head and neck mucosal melanoma.

Authors:  Fernando López; Juan P Rodrigo; Antonio Cardesa; Asterios Triantafyllou; Kenneth O Devaney; William M Mendenhall; Missak Haigentz; Primož Strojan; Phillip K Pellitteri; Carol R Bradford; Ashok R Shaha; Jennifer L Hunt; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-05-22       Impact factor: 3.147

10.  Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.

Authors:  Ana Slipicevic; Geir Frode Øy; Anne Katrine Ree Rosnes; Øystein Stakkestad; Elisabeth Emilsen; Birgit Engesæter; Gunhild M Mælandsmo; Vivi Ann Flørenes
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.